Search

Displaying results 9871 - 9880 of 10000 in total
  1. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  2. Drug

    Cantuzumab ravtansine

    go.drugbank.com/drugs/DB05594
    Investigational

  3. Drug

    Farletuzumab

    go.drugbank.com/drugs/DB05595
    Investigational

    Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

  4. Drug

    OTI-030

    go.drugbank.com/drugs/DB05648
    Investigational

  5. Drug

    Iodofiltic acid I-123

    go.drugbank.com/drugs/DB05683
    Investigational

  6. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

  7. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

  8. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties.

    Synonyms: RPI-MN
  9. Drug

    Bucainide

    go.drugbank.com/drugs/DB20650
    Experimental

    The usage of the INN stem '-cain-' in the name indicates that Bucainide is a class I antiarrhythmic, procainamide and lidocaine derivative. Bucainide has a monoisotopic molecular weight of 329.28 Da.

  10. Drug

    Cathine

    go.drugbank.com/drugs/DB01486
    ExperimentalIllicit

    In the United States, it is classified as a Schedule IV controlled substance.